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Background: Agoraphobia is considered to be the most serious complication of panic disorder. 
It involves progressive development of debilitating anxiety symptoms related to being in 
  situations where one would be extremely embarrassed and could not be rescued in the case of 
a panic attack. This study aimed to investigate the efficacy of noninvasive brain stimulation 
using a radioelectric asymmetric conveyor (REAC) for agoraphobia.
Patients and methods: Twenty-three patients (3 males and 20 females) suffering from 
agoraphobia and without a history of panic disorder were evaluated by a psychiatrist using the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and the 
Agoraphobia Scale (AS). The patients were subjected to two 18-session cycles of noninvasive 
brain stimulation with the REAC, according to an established therapeutic protocol called neuro-
psycho-physical optimization.
Results: Analyzing the anxiety and avoidance parameters of the AS after the first and second 
cycles of REAC treatment revealed variation in levels of response to treatment, including weak 
(AS item 7), moderate (AS items 10 and 13), and good responses (AS items 1–6, 8, 9, 11, 12, 
and 14–20).
Conclusion: These results highlight the potential of the REAC to treat complex clinical 
situations such as agoraphobia, which is typically resistant to pharmacologic treatments. 
  Furthermore, these data show the advantages of REAC treatment, even compared with modern 
cognitive behavioral therapy, including a relatively rapid and “stable” clinical response (just 
over 6 months) and economic cost.
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Introduction
Agoraphobia is considered to be the most serious complication of panic disorder. 
According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (DSM-IV-TR),1–3 agoraphobia is a progressive development 
of debilitating anxiety symptoms related to being in situations where one would be 
extremely embarrassed and could not be rescued in the case of a panic attack.
The typical constellation of agoraphobic symptoms emerges in specific 
  circumstances4 such as being out of the house alone or in the midst of many unknown 
people, waiting in line, navigating a bridge or tunnel, or traveling by car, bus, plane, or 
train. Furthermore, other less common manifestations of agoraphobia such as the need 
to wear sunglasses, carry items such as a bottle of water or anti-anxiety medications,   
or being unable to wear a turtleneck, necktie, or even a ring have been described.5 
Therefore, an agoraphobic person tends to avoid places and/or situations that may Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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induce a panic attack, and, if the individual must be in these 
situations, they experience extreme discomfort and the 
conviction of an imminent panic attack.5 In many affected 
individuals, this develops into an uncontrollable need to use 
a “companion guide” – defined as a trusted person, usually 
a friend or relative – to cope with the more common acts of 
normal social life. Although agoraphobia is a complication/
consequence of panic disorder, the DSM-IV-TR also describes 
agoraphobia without a history of panic disorder. This condi-
tion is difficult to assess but it seems to affect between 0.6% 
and 6% of the general population, especially women.1,6,7 
However, it is widely believed that agoraphobia is always 
preceded by panic attacks, which may be triggered by specific, 
well-demonstrated factors or may be subthreshold8 with an 
atypical manifestation. According to this conceptual approach, 
panic disorder always begins with recurrent, unexpected panic 
attacks, which occur in typical neurovegetative form due to 
activation of the locus coeruleus,9–11 less frequently, and bio-
electrical desynchronization of the temporal lobes, causing 
depersonalization–derealization panic-related syndrome. In 
the next stage, the complex of anticipatory and intercritical 
anxiety arises, caused by persistent limbic activation. Finally, 
agoraphobia develops, supported by a progressive pattern of 
cortical processing, fear, and avoidance.
Pharmacologic treatment of panic disorder and anticipatory 
and intercritical anxiety with selective serotonin reuptake 
inhibitors and serotonin and norepinephrine reuptake 
inhibitors has excellent results. However,   agoraphobia remains 
largely refractory to these approaches, and only sporadic 
and inconclusive data support the effectiveness of cognitive 
behavioral psychotherapy.12–17 Therefore, this study aimed to 
investigate the efficacy of noninvasive brain stimulation using a 
radioelectric asymmetric conveyor (REAC) for agoraphobia.
Materials and methods
Patients
Twenty-three patients (3 males, 20 females) participated in 
this study. Mean age of onset was 29.4 ± 2.4 years, mean 
age when diagnosis was made was 36.6 ± 1.8 years, and 
age range was 34–41 years. Patients were referred to our 
institute with a diagnosis of agoraphobia without a history of 
panic disorder. All patients were evaluated by a psychiatrist 
according to DSM-IV-TR criteria2,3,18 and all were assessed 
using the Agoraphobia Scale (AS).19
The As
The AS19 is a self-administered questionnaire and consists 
of 20 items divided into two sections that describe common 
agoraphobic situations. Since anxiety can be present in 
absence of avoidance and (more rarely) vice versa, the 
first section of this psychometric instrument captures the 
anxiety parameters and is rated from 0 (no anxiety) to 4 
(extreme   anxiety). The second section captures the   avoidance 
parameters and is rated from 0 (absent avoidance) to 2 
  (constant avoidance). The AS was administered in this study 
by a team of psychiatrists at baseline screening (t0) and about 
1 month after the end of the first (t1) and second (t2) cycles of 
noninvasive brain stimulation. The AS is easy for the patient 
to complete and takes about 10 minutes.
The reAc device
The REAC20,21 is a medical biostimulation device based 
on innovative technology. The model used in this study 
(Convogliatore di Radianza Modulante; ASMED,   Florence, 
Italy) is specific for noninvasive brain stimulation 
techniques.
Patients underwent noninvasive brain stimulation 
REAC treatment, according to the standardized protocol 
of neuro-psycho-physical-optimization (NPPO). The 
REAC-NPPO treatment protocol consisted of seven radio 
Table 1 Agoraphobia scale items
Item Description
1 Being alone in your home
2 shopping unaccompanied in small shops (eg, a grocery, 
pharmacy, etc)
3 crossing a street in the city alone
4 Being in a crowd unaccompanied
5 Traveling on a bus unaccompanied, when it is crowded
6 Walking straight across large open spaces in the city  
(eg, a square)
7 Driving a car alone through a long tunnel
8 Walking away from your home alone
9 Traveling by train or underground unaccompanied, when it is 
crowded
10 Standing unaccompanied in a long queue in a post office, bank, 
supermarket, etc
11 sitting on a chair for a long time, when in the company of 
other people
12 eating at a restaurant or café
13 sitting in the middle of a row at a cinema or theater
14 shopping unaccompanied in a department store that is full  
of people
15 Walking over a bridge when there are a lot of people and 
traffic about
16 Driving a car alone over a bridge
17 having a haircut at the hairdresser, unaccompanied
18 shopping unaccompanied in a large supermarket, crowded 
with people
19 Walking in a crowded street unaccompanied
20 riding in an elevator unaccompaniedPatient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Results
At baseline (t0), the average total AS score for all items 
(Table 1) for “anxiety” was 3.3 ± 0.3, corresponding to a 
“severe” clinical picture, while the average total score for 
all items relating to “avoidance” was 1.5 ± 0.3, indicating 
strong and very frequent avoidant behavior. Approximately 
1 month after the end of the first cycle (t1) of REAC-NPPO 
therapy, the average total AS score of all the items for 
“anxiety” decreased slightly, to 2.8 ± 1.6, corresponding 
to a clinical picture pathologically less important than that 
observed at t0, but not significant from a statistical point 
of view, at least in general terms. In fact, the relative score 
for “anxiety” for some items such as 1, 20, and 3 were 
significantly reduced.
The same holds with regard to the average total AS 
score for all the items for “avoidance” reduced to 1.3 ± 0.4, 
although, also in this case, the abovementioned items were 
significantly decreased. Approximately 1 month after the end 
of the second cycle (t2) of REAC-NPPO therapy, the aver-
age total AS score for all the items for “anxiety” decreased 
significantly, to 2.4 ± 0.4, and the average total AS score for 
all the items for “avoidance” also decreased significantly, 
frequency bursts of 500 milliseconds each at a frequency of 
10.5 GHz and with a specific absorption rate of 7 µW/kg, 
applied by touching the metallic tip of the REAC probe to 
the pavilion of the ear. REAC treatment has proven efficacy 
in ameliorating several stress-related disorders,22–26 as well 
as depression,26–28 anxiety,26,28 bipolar disorder,29 and some 
forms of dementia.30
The REAC treatment protocol for this study consisted 
of two 18-session cycles of brain stimulation applied to the 
ear. In every session, seven specific points of the pavilion of 
the ear were stimulated, and this noninvasive and painless 
procedure lasted about 3.5 seconds. The first REAC treatment 
cycle was separated from the following cycle by an interval 
of about 6 months.
statistical analysis
Two statistical tests, the Wilcoxon signed-rank test and 
the Sign test, were used to compare the mean and standard 
deviation of all AS items for anxiety and for avoidance between 
pairs of timepoints (t1 and t0; t2 and t0; t2 and t1). Variation 
in AS item scores was used to determine which items showed 
low, medium, and good responses to REAC treatment.
Table 2 Agoraphobia scale: anxiety
Item Average change (%) Statistical test
Wilcoxon Z; Asymp Sig Sign test Exact Sig
t1–t0 t2–t0 t2–t1 t1–t0 t2–t0 t2–t1 t1–t0 t2–t0 t2–t1
Significant response to treatment
1 64.10 74.36 28.57 -4.28; 0.000 -4.33; 0.000 -4.28; 0.000 0.000 0.000 0.008
2 22.37 72.37 64.41 -3.69; 0.000 -4.33; 0.000 -3.69; 0.000 0.000 0.000 0.000
3 66.67 74.36 23.08 -4.28; 0.000 -4.33; 0.000 -4.28; 0.034 0.000 0.000 0.063
4 22.37 72.37 64.41 -3.37; 0.001 -4.33; 0.000 -3.37; 0.000 0.001 0.000 0.000
5 22.37 73.68 66.10 -3.49; 0.000 -4.33; 0.000 -3.49 0.000 0.000 0.000 0.000
6 21.33 72.00 64.41 -2.96; 0.003 -4.29; 0.000 -2.96; 0.000 0.003 0.000 0.000
8 21.33 72.00 64.41 -3.02; 0.000 -4.32; 0.000 -4.32; 0.000 0.001 0.000 0.000
9 22.37 73.68 66.10 -3.49; 0.000 -4.31; 0.000 -4.39; 0.000 0.000 0.000 0.000
11 22.37 73.68 66.10 -3.49; 0.000 -4.33; 0.000 -4.34; 0.000 0.000 0.000 0.000
12 22.37 72.37 64.41 -3.69; 0.000 -4.36; 0.000 -4.32; 0.000 0.000 0.000 0.000
14 23.38 72.73 64.41 -3.22; 0.001 -4.31; 0.000 -4.32; 0.000 0.001 0.000 0.000
15 22.37 73.68 66.10 -3.49; 0.000 -4.33; 0.000 -4.34; 0.000 0.000 0.000 0.000
16 25.32 73.42 64.41 -3.54; 0.000 -4.33; 0.000 -4.32; 0.000 0.000 0.000 0.000
17 22.37 73.68 66.10 -3.54; 0.000 -4.27; 0.000 -4.39; 0.000 0.000 0.000 0.000
18 22.37 72.37 64.41 -3.22; 0.001 -4.27; 0.000 -4.32; 0.000 0.001 0.000 0.000
19 36.84 73.68 58.33 -4.32; 0.000 -4.33; 0.000 -4.46; 0.000 0.000 0.000 0.000
20 55.26 72.37 38.24 -4.17; 0.000 -4.27; 0.000 -3.36; 0.001 0.000 0.000 0.000
Moderate response to treatment
10 22.37 72.37 64.41 -2.76; 0.006 -3.36; 0.001 -2.00; 0.046 0.004 0.000 0.125
13 66.67 74.36 23.08 -3.22; 0.001 -3.46; 0.001 -2.24; 0.025 0.001 0.000 0.063
Low response to treatment
7 1.28 2.56 1.30 -1.00; 0.317 -1.41; 0.157 -1.00; 0.317 nr* 0.500 nr*
Note: *sign test algorithm gave no response value in this instable case.
Abbreviations: Asymp Sig, asymptotic significance (two-tailed); Exact Sig, exact significance (two-tailed); NR, no response.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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to 0.9 ± 0.2. Furthermore, with respect to t0, some items 
showed an even greater statistical significance, especially 
for “avoidance”: specifically, items 1, 20, and 3.
Globally, in the comparison between t2 and t0, item-
by-item analysis showed a weak response to treatment 
for anxiety (Table 2) and avoidance (Table 3) on item 7. 
A moderate response was observed for items 10 and 13. 
A good, statistically significant response was observed for 
items 1–6, 9, 11, 12, and 14–20.
Discussion
The current results highlight the potential of REAC brain 
stimulation for the treatment of complex and chronic 
clinical conditions such as agoraphobia that are typically 
resistant to current pharmacologic treatments. The relatively 
rapid therapeutic effect, appearing in just a few months, 
highlights important time and economic advantages, even 
in comparison with novel cognitive behavioral treatment 
strategies. In general terms, the anxiety component of this 
clinical condition improved from very severe and pervasive 
to limited severity, and the avoidance component improved 
from disabling to subthreshold and manageable picture. 
Therefore, on the basis of clinical observation and the 
reductions in total AS scores, the response to REAC-NPPO 
therapy appears to be very favorable. It is interesting to 
note that, compared with previous studies published on 
bipolar disorder,29 panic disorder,27 generalized anxiety 
disorder,25,26,28 Alzheimer’s disease,30 and various stress-
related disorders,22–26 the response of agoraphobia to REAC-
NPPO therapy was slower and less robust, as significant 
improvement on anxiety and avoidance was not present at 
the first timepoint (t1). One possible explanation for this 
could be that agoraphobia may be a secondary complication 
of the primary disorder (ie, panic disorder) and would 
therefore be less affected by treatment, similar to the effects 
of treatment on alcohol dependence in an individual with 
social anxiety disorder. Another explanation could be that 
the long interval of time between the onset and diagnosis of 
agoraphobia delays the first therapeutic attempt. This critical 
delay may favor establishment of neuroanatomical circuitry 
that supports agoraphobic thoughts and related avoidant 
behaviors. Finally, agoraphobia without symptoms of panic 
Table 3 Agoraphobia scale: avoidance
Item Average change (%) Statistical test
Wilcoxon Z; Asymp Sig Sign test Exact Sig
t1–t0 t2–t0 t2–t1 t1–t0 t2–t0 t2–t1 t1–t0 t2–t0 t2–t1
Significant response to treatment
1 64.10 74.36 28.57 -4.28; 0.000 -4.33; 0.000 -4.28; 0.000 0.000 0.000 0.008
2 22.37 72.37 64.41 -3.69; 0.000 -4.33; 0.000 -3.69; 0.000 0.000 0.000 0.000
3 66.67 74.36 23.08 -4.28; 0.000 -4.33; 0.000 -4.28; 0.034 0.000 0.000 0.063
4 22.37 72.37 64.41 -3.37; 0.001 -4.33; 0.000 -3.37; 0.000 0.001 0.000 0.000
5 22.37 73.68 66.10 -3.49; 0.000 -4.33; 0.000 -3.49 0.000 0.000 0.000 0.000
6 21.33 72.00 64.41 -2.96; 0.003 -4.29; 0.000 -2.96; 0.000 0.003 0.000 0.000
8 21.33 72.00 64.41 -3.02; 0.000 -4.32; 0.000 -4.32; 0.000 0.001 0.000 0.000
9 22.37 73.68 66.10 -3.49; 0.000 -4.31; 0.000 -4.39; 0.000 0.000 0.000 0.000
11 22.37 73.68 66.10 -3.49; 0.000 -4.33; 0.000 -4.34; 0.000 0.000 0.000 0.000
12 22.37 72.37 64.41 -3.69; 0.000 -4.36; 0.000 -4.32; 0.000 0.000 0.000 0.000
14 23.38 72.73 64.41 -3.22; 0.001 -4.31; 0.000 -4.32; 0.000 0.001 0.000 0.000
15 22.37 73.68 66.10 -3.49; 0.000 -4.33; 0.000 -4.34; 0.000 0.000 0.000 0.000
16 25.32 73.42 64.41 -3.54; 0.000 -4.33; 0.000 -4.32; 0.000 0.000 0.000 0.000
17 22.37 73.68 66.10 -3.54; 0.000 -4.27; 0.000 -4.39; 0.000 0.000 0.000 0.000
18 22.37 72.37 64.41 -3.22; 0.001 -4.27; 0.000 -4.32; 0.000 0.001 0.000 0.000
19 36.84 73.68 58.33 -4.32; 0.000 -4.33; 0.000 -4.46; 0.000 0.000 0.000 0.000
20 55.26 72.37 38.24 -4.17; 0.000 -4.27; 0.000 -3.36; 0.001 0.000 0.000 0.000
Moderate response to treatment
10 22.37 72.37 64.41 -2.76; 0.006 -3.36; 0.001 -2.00; 0.046 0.004 0.000 0.125
13 66.67 74.36 23.08 -3.22; 0.001 -3.46; 0.001 -2.24; 0.025 0.001 0.000 0.063
Low response to treatment
7 1.28 2.56 1.30 -1.00; 0.317 -1.41; 0.157 -1.00; 0.317 nr* 0.500 nr*
Note: *sign test algorithm gave no response value in this instable case.
Abbreviations: Asymp Sig, asymptotic significance (two-tailed); Exact Sig, exact significance (two-tailed); NR, no response.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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disorder does not usually appear suddenly and severely; 
rather, it subtly insinuates itself, gradually influencing 
thoughts and attitudes and preventing an individual from 
mobilizing appropriate defense strategies. However, as 
previously noted, some AS items had already improved after 
the first cycle of REAC-NPPO therapy. This suggests that 
qualitative analysis of clinical data is justified to determine 
the health status of the individual. Using this approach, the 
majority of the patients felt globally better after the first 
cycle of REAC-NPPO therapy, and this effect was close to 
statistical significance. After the second cycle of treatment, 
the improvement from baseline was more evident. In fact, 
one of the most interesting features of REAC-NPPO is the 
enhancement in efficacy observed across repeated cycles. In 
addition and according to our experience about this peculiar 
kind of brain stimulation, it is important to discontinue 
therapy for a period of 4–6 months. This interval may allow 
a sort of “deep reorganization” (optimization) of brain and/or 
mental functions, as with agoraphobia, where the tendency 
to avoid harm overcomes other survival parameters, such as 
novelty seeking and reward dependence.
Conclusion
Although this was an open-label, naturalistic study conducted 
on a small number of patients, it was the first study to explore 
the potential of brain stimulation in a clinical disorder such 
as agoraphobia, a disorder with no clear organic framework. 
The refractory nature of agoraphobia to current treatments, 
combined with the great suffering and progressive functional 
impairment of patients, necessitates development of new 
therapeutic strategies to promote social rehabilitation. The 
unique, noninvasive brain stimulation achieved by REAC 
appears very promising because of its high tolerability and 
good safety profile.
Clearly, considering the obvious limitations, more 
rigorous studies should investigate the effects of REAC in 
double-blind, placebo-controlled designs in a larger sample to 
determine the potential of this approach for agoraphobia and 
other, similar conditions. Furthermore, since agoraphobia is 
a chronic condition, longer observation periods are needed; 
this may also help to reduce any possible and nonspecific 
positive role that can be produced through the enthusiasm of 
being subjected to an innovative treatment technology.
Disclosure
Salvatore Rinaldi and Vania Fontani are the inventors of 
the REAC.
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